Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stock

On July 7, Cathie Wood's Ark Genomic Revolution ETF (NYSEMKT: ARKG) sold implicit 44,000 shares of BioNTech (NASDAQ: BNTX), a German immunotherapy maker. The adjacent day, it sold implicit 78,000 shares, a transaction valued astatine astir $7.4 million.

As of July 10, that near her plus absorption institution with conscionable 307 shares, valued astatine a small much than $28,000. Because Ark Invest holds positions worthy millions of dollars and BioNTech is present the smallest holding successful this full exchange-traded money (ETF), it whitethorn beryllium just to presume that Wood has moved connected from BioNTech.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

What whitethorn person caused BioNTech to get the footwear

One happening to cognize astir ARKG is that it's an actively managed ETF, truthful it's communal for the money to determination successful and retired of stocks frequently.

Because Wood's ETF has present sold astir of its BioNTech shares, it appears to beryllium moving on, freeing up superior for Ark Invest. BioNTech banal has underperformed this year; arsenic of this writing, its terms is down astir 4% twelvemonth to day and has dipped much than 17% implicit the past 12 months. But determination are challenges up that could proceed to nonstop shares lower.

One is that gross is expected to onshore determination betwixt 2 cardinal euros ($2.2 billion) and 2.3 cardinal euros ($2.6 billion) successful 2026, a important alteration from the 2.9 cardinal euros ($3.3 billion) reported for 2025. That's mostly owed to an expected driblet successful gross from its COVID-19 vaccine, developed successful concern with Pfizer.

Another fiscal contented is that BioNTech reported back-to-back nett losses successful 2024 and 2025, aft a nett net of 900 cardinal euros ($1 billion) successful 2023. That inclination of nett losses volition apt continue, arsenic BioNTech already showed a nett nonaccomplishment successful its 2026 first-quarter net report.

There are besides issues connected the enactment front. BioNTech's co-founders, Uğur Şahin and Özlem Türeci, are leaving the institution by the extremity of 2026. Şahin is the CEO, and Türeci is the main aesculapian officer, truthful those are important roles to fill. What makes that enactment modulation adjacent much challenging is that BioNTech has been shifting its absorption from vaccines to oncology treatments.

Is it clip to merchantability BioNTech?

The determination from Ark Invest is notable. While investors shouldn't automatically travel its pb successful selling the stock, BioNTech is trying to flooded respective challenges astatine once. The institution has a promising objective pipeline of much than 25 signifier 2 oregon signifier 3 trials successful oncology, but it lone has 1 commercialized merchandise -- that COVID vaccine with slumping sales. All of this is analyzable by the request to find caller leadership.